Current and future use of positron emission tomography (PET) in breast cancer.
Positron emission tomography (PET) is a radiotracer imaging method that is increasingly used in both the clinical care of breast cancer patients and in translational breast cancer research. This review emphasizes current and future clinical applications of PET to breast cancer, and highlights some translational research using PET to elucidate the clinical biology of breast cancer. PET principles are reviewed, followed by a review of current applications of (18)F-fluorodeoxyglucose (FDG) to clinical breast cancer care. Finally we review work done with other radiopharmaceuticals beyond FDG designed to image a number of aspects of breast cancer biology, emphasizing those most likely to enter clinical trials in the near future.
Mankoff
David A
DA
Division of Nuclear Medicine, Department of Radiology, University of Washington and Seattle Cancer Care Alliance, Seattle, WA, USA.
Eubank
William B
WB
D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000556:secondary; D005260:Female; D019788:Fluorodeoxyglucose F18; D005544:Forecasting; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging* / Q000473:pathology; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging*; D009367:Neoplasm Staging / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods / Q000639:trends*; D011300:Preoperative Care; D011379:Prognosis; D012680:Sensitivity and Specificity; D021701:Sentinel Lymph Node Biopsy / Q000379:methods
D019788:Fluorodeoxyglucose F18